IMI Announces First Acceptance of Patent for Color Measurement Process

IMI Announces First Acceptance of Patent for Color Measurement
Process
Technology used in PREVU(x) Skin Sterol Test as well as cancer products 


TORONTO, March 31  /PRNewswire-FirstCall/ -- Leading predictive medicine
company IMI International Medical Innovations Inc. (TSX: IMI; Amex: IME) today
announced that its application for a new patent, titled Color Space Analysis in
Biochemical and Immunological Assays, has been accepted by the Australian
Patent Office.

The patent covers the process for quantifying a color change reaction that is
related to the presence of disease in humans. This color-reading system is used
throughout IMI's product portfolio as part of the PREVU(x) Skin Sterol Test, a
non-invasive predictive test for coronary artery disease, and in IMI's cancer
detection tests, ColorectAlert(TM), LungAlert(TM) and a breast cancer test.

Australia is the first territory in which this patent application has been
accepted. This same patent is pending in the U.S., Europe, Brazil, China,
Russia, Hong Kong, India and Japan.

"This patent is an important part of a strategic portfolio that enables IMI to
set the standard for innovation in the predictive medicine field," said Dr.
Brent Norton, President and Chief Executive Officer. "It further protects our
cancer and skin sterol technologies and bolsters our intellectual property
position internationally. Moreover, it opens the door to new growth and
licensing opportunities for our color-reading capability as a platform for
accurately quantifying human biologic reactions. IMI can now apply this unique
process to new technologies where measurement has to date been challenging."

IMI maintains a diverse portfolio of intellectual property, such as trademarks,
trade secrets, and technological know-how. IMI's objective is to develop and
control all relevant technologies that could be applied to its products. IMI's
intellectual property portfolio currently includes 36 issued patents and
patents pending related to the skin sterol technology, 23 patents and patents
pending related to IMI's cancer technologies and nine patents and patents
pending related to the color measurement process.

About IMI

IMI (http://www.imimedical.com/) is a world leader in predictive medicine,
dedicated to developing rapid, non-invasive tests for the early detection of
life-threatening diseases. IMI's cardiovascular products, which are branded as
PREVU(x) Skin Sterol Test, are marketed and distributed worldwide by McNeil
Consumer Healthcare, Canada. The company's cancer tests include
ColorectAlert(TM), LungAlert(TM) and a breast cancer test. IMI's head office is
located in Toronto, and its research and product development facility is at
McMaster University in Hamilton, Ontario. For information regarding PREVU(x),
please go visit http://www.prevu.com/.

This press release contains forward-looking statements. These statements
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward-looking
statements. Such risks and uncertainties include, among others, the lack of
operating profit and availability of funds and resources to pursue R&D
projects, the successful and timely completion of clinical studies, the
successful development or marketing of the Company's products, reliance on
third-party manufacturers, the competitiveness of the Company's products if
successfully commercialized, the ability of the Company to take advantage of
business opportunities, uncertainties related to the regulatory process, and
general changes in economic conditions. In addition, while the Company
routinely obtains patents for its products and technology, the protection
offered by the Company's patents and patent applications may be challenged,
invalidated or circumvented by our competitors and there can be no guarantee of
our ability to obtain or maintain patent protection for our products or product
candidates.

Investors should consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information on risks
and uncertainties relating to the forward-looking statements. Investors are
cautioned not to rely on these forward-looking statements. IMI is providing
this information as of the date of this press release and does not undertake
any obligation to update any forward-looking statements contained in this press
release as a result of new information, future events or otherwise. 

DATASOURCE: IMI International Medical Innovations Inc.



CONTACT: Company Contact: Sarah Borg-Olivier, Director, Communications,

T: [phone], ; U.S. Investor Contact:

Andrea Faville, Edward Abella, The Investor Relations Group, T:

[phone], ,

Copyright